B
KRYS icon

Braidwell’s Krystal Biotech KRYS Stock Holding History

Braidwell’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.9M Sell
128,975
-53,450
-29% -$16M 1.77% 17
2026
Q1 		$47.1M Sell
182,425
-19,676
-10% -$5.24M 1.57% 20
2025
Q4 		$49.8M Sell
202,101
-318,300
-61% -$67M 1.59% 24
2025
Q3 		$91.9M Sell
520,401
-207,410
-28% -$31M 2.73% 8
2025
Q2 		$100M Buy
727,811
+327,067
+82% +$48M 3.42% 8
2025
Q1 		$72.3M Buy
400,744
+200,244
+100% +$33.7M 2.54% 13
2024
Q4 		$31.4M Buy
200,500
+31,809
+19% +$5.64M 0.93% 40
2024
Q3 		$30.7M Buy
168,691
+61,512
+57% +$11.9M 0.87% 42
2024
Q2 		$19.7M Sell
107,179
-69,910
-39% -$11.7M 0.62% 47
2024
Q1 		$31.5M Sell
177,089
-19,111
-10% -$2.65M 1.02% 38
2023
Q4 		$24.3M Buy
196,200
+118,703
+153% +$13.2M 0.89% 38
2023
Q3 		$8.99M Sell
77,497
-163,902
-68% -$20M 0.28% 80
2023
Q2 		$28.3M Sell
241,399
-106,637
-31% -$10.9M 0.93% 39
2023
Q1 		$27.9M Sell
348,036
-10,020
-3% -$787K 0.92% 43
2022
Q4 		$28.4M Buy
+358,056
New +$26.6M 0.95% 41

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Braidwell's KRYS Position: Q2 2026 in Review

Braidwell reduced its Krystal Biotech (KRYS) stake by 29% in Q2 2026, selling an estimated $16M and leaving 128,975 shares worth $47.9M. The position accounts for 1.77% of the portfolio, ranked #17.

Braidwell first reported a position in KRYS in Q4 2022 and has held it in 15 quarters since. The position peaked at $100M in Q2 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Braidwell held 128,975 shares of Krystal Biotech worth $47.9M as of Q2 2026.
  • Braidwell sold 53,450 Krystal Biotech shares in Q2 2026, an estimated $16M.
  • Krystal Biotech made up 1.77% of Braidwell's portfolio in Q2 2026, its #17 holding.
  • Braidwell first reported a position in Krystal Biotech in Q4 2022 and has held it in 15 quarters since.
  • Braidwell's Krystal Biotech position peaked at $100M in Q2 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.